Pharmathen competitive analysis

Explore patent oppositions filed by Pharmathen against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
S1P Receptor Modulators For Treating Multiple SclerosisNOVARTISOct 12, 2022
Injectable Suspensions Having Improved Injectability PropertiesALKERMES CONTROLLED THERAPEUTICSDec 21, 2016
Injectable Suspensions Having Improved Injectability PropertiesALKERMES CONTROLLED THERAPEUTICSDec 14, 2016
Polymer-Based Sustained Release DeviceALKERMES PHARMA IRELANDNov 16, 2015
Exendin For Treating Diabetes And Reducing Body WeightAMYLIN PHARMACEUTICALSAug 17, 2015

Explore Pharmathen's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
Feb 8, 2023Preparation Of Polylactide-Polyglycolide Microparticles Having A Sigmoidal Release Profile1

Latest PTAB cases involving Pharmathen

Discover the latest PTAB cases involving Pharmathen, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Pharmathen with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
PHARMATHEN51 - -
ALKERMES CONTROLLED THERAPEUTICS - 5 - 2
ALKERMES PHARMA IRELAND61812
AMYLIN PHARMACEUTICALS - 12 - 4